Sale on Ophthalmic Equipment - Starting from 16 November!
The White House has withdrawn Heidi Overton’s FDA commissioner nomination, leaving Kyle Diamantas as acting head, and analysts expect no major disruption for now.
The White House has withdrawn its FDA commissioner nomination for Heidi Overton. The Food and Drug Administration has had only an acting leader since May. Reports say her views on vaccines, abortion drugs and flavoured vapes cost her support in the Senate.
The Senate Health, Education, Labor and Pensions Committee had planned a Wednesday vote on Overton alongside other nominees. The White House wanted her in place while Republicans still control Congress. Axios reported on Tuesday that the administration had dropped the effort because her confirmation looked unlikely. No vote took place.
Chairman Bill Cassidy, a Louisiana Republican, confirmed the outcome at the hearing and said he was surprised. He said he believed she would have won enough votes in committee and in the full Senate. With little time left, he said "confirming a permanent FDA commissioner appears to fall to Senate Democrats".
Kyle Diamantas, the agency's deputy commissioner for food, has been acting commissioner since May. He took over after Marty Makary resigned following a tenure marked by leadership turnover and unpredictable decisions. Federal law limits an acting commissioner to 210 days, and the withdrawal resets that clock. In recent months the agency has undone many of Makary's contested choices and put more conventional leaders in charge of two senior drug offices.
At her September hearing, Overton promised to act within the law on vaccine policy and accepted that mifepristone had cleared the FDA's safety and effectiveness bar. A new FDA review of that drug is under way, with results expected by March 2027. She also favoured policies to speed rare disease drug development and promised more expert panels. She backed President Trump's plan to split the MMR vaccine into three shots. Her part in loosening access to flavoured vapes reportedly drew opposition from some MAHA groups and Republican lawmakers.
A fresh FDA commissioner nomination could take months. It is unclear who the administration will choose. Semafor reported that Republican Senator Roger Marshall, a physician who lost his Kansas bid for another term, could be the pick. RBC Capital Markets analyst Brian Abrahams wrote that agency operations are "likely to continue running reasonably smoothly". He cautioned that the sector "could potentially see more instability" if Diamantas leaves.
The FDA commissioner nomination outcome may matter to device makers and buyers, because clearances and enforcement depend on a steady agency. Analysts expect no major disruption for now. Medigear.uk helps clinical buyers compare verified suppliers. UK buyers should note that the MHRA, not the FDA, regulates devices in Great Britain. Views here belong to the people quoted.
Source: BioPharma Dive
Tell us the model and destination — our sourcing team will respond within one business day.

The Zimmer Monogram robot is now with US regulators. Zimmer Biomet has filed a 510(k) submission for…

The Abbott Encantor trial has begun. Abbott said on Thursday that it has started the VOYAGER CE clin…

Johnson & Johnson (J&J) said on Thursday that a Houston hospital will be the first to instal…
Approvals, trials, recalls and market moves — the essentials for procurement and clinical teams.